Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Heart damage present in 54% of COVID-19 patients after discharge | Intelerad acquires Lumedx | AI predicts AFib
Friday, February 19, 2021
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

A month after discharge, heart damage still present in 54% of COVID-19 patients with raised troponin levels

“Importantly, the pattern of damage to the heart was variable, suggesting that the heart is at risk of different types of injury,” one researcher said. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

A month after discharge, heart damage still present in 54% of COVID-19 patients with raised troponin levels

Share on Twitter Share on Facebook Share on Linkedin
“Importantly, the pattern of damage to the heart was variable, suggesting that the heart is at risk of different types of injury,” one researcher said. 
READ MORE >

Intelerad Medical Systems acquires Lumedx

Intelerad Medical Systems has acquired Lumedx, an Oakland, California-based healthcare technology company focused on analytics and cardiovascular information systems. This is Intelerad’s third acquisition in the last seven months.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Intelerad Medical Systems acquires Lumedx

Share on Twitter Share on Facebook Share on Linkedin
Intelerad Medical Systems has acquired Lumedx, an Oakland, California-based healthcare technology company focused on analytics and cardiovascular information systems. This is Intelerad’s third acquisition in the last seven months.
READ MORE >

AI predicts new-onset AFib using 12-lead ECGs

The team's deep neural network was trained on more than 1.6 million 12-lead ECGs. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

AI predicts new-onset AFib using 12-lead ECGs

Share on Twitter Share on Facebook Share on Linkedin
The team's deep neural network was trained on more than 1.6 million 12-lead ECGs. 
READ MORE >

Featured Articles

Bernard Lown, groundbreaking cardiologist and influential antiwar activist, dies at 99

Lown was an innovator in the field of arrhythmia research and led the development of the direct current defibrillator. He also helped found an organization that won the Nobel Peace Prize in 1985. 

READ MORE >
Bernard Lown, MD
Share on Twitter Share on Facebook Share on Linkedin

Bernard Lown, groundbreaking cardiologist and influential antiwar activist, dies at 99

Share on Twitter Share on Facebook Share on Linkedin
Bernard Lown, MD
Lown was an innovator in the field of arrhythmia research and led the development of the direct current defibrillator. He also helped found an organization that won the Nobel Peace Prize in 1985. 
READ MORE >

FDA approves expanded indication for sacubitril/valsartan

Manufactured by Novartis under the name Entresto, the medication is now also approved for treating HFpEF. 

READ MORE >
Large peridevice leaks after left atrial appendage occlusion (LAAO) are incredibly rare and not associated with a greater risk of adverse outcomes, according to new research published in JACC: Clinical Electrophysiology.[1] Smaller residual links are more common, however, and associated with a risk of thromboembolic and bleeding events.
Share on Twitter Share on Facebook Share on Linkedin

FDA approves expanded indication for sacubitril/valsartan

Share on Twitter Share on Facebook Share on Linkedin
Large peridevice leaks after left atrial appendage occlusion (LAAO) are incredibly rare and not associated with a greater risk of adverse outcomes, according to new research published in JACC: Clinical Electrophysiology.[1] Smaller residual links are more common, however, and associated with a risk of thromboembolic and bleeding events.
Manufactured by Novartis under the name Entresto, the medication is now also approved for treating HFpEF. 
READ MORE >

Heart failure medication may offer relief for patients with COVID-related POTS

Overall, researchers found that ivabradine was a “safe and effective” POTS treatment associated with making significant improvements to patient heart rates and quality of life.

READ MORE >
Even patients who were never hospitalized for COVID-19 face a heightened risk of cardiovascular issues. #longcovid
Share on Twitter Share on Facebook Share on Linkedin

Heart failure medication may offer relief for patients with COVID-related POTS

Share on Twitter Share on Facebook Share on Linkedin
Even patients who were never hospitalized for COVID-19 face a heightened risk of cardiovascular issues. #longcovid
Overall, researchers found that ivabradine was a “safe and effective” POTS treatment associated with making significant improvements to patient heart rates and quality of life.
READ MORE >

Living an active lifestyle reduces chances of dying immediately after a heart attack

The study, published in the European Journal of Preventive Cardiology, included data from more than 28,000 patients. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Living an active lifestyle reduces chances of dying immediately after a heart attack

Share on Twitter Share on Facebook Share on Linkedin
The study, published in the European Journal of Preventive Cardiology, included data from more than 28,000 patients. 
READ MORE >

In Other News

Everyday people photos equip AI for skin-cancer screening

AI can be taught to flag possible skin cancers on photos taken with smartphone cameras—and the images can be ordinary “people shots” rather than closeups of suspicious lesions.

READ MORE >
Sunburn
Share on Twitter Share on Facebook Share on Linkedin

Everyday people photos equip AI for skin-cancer screening

Share on Twitter Share on Facebook Share on Linkedin
Sunburn
AI can be taught to flag possible skin cancers on photos taken with smartphone cameras—and the images can be ordinary “people shots” rather than closeups of suspicious lesions.
READ MORE >

How one hospital bolstered incidental lung nodule follow-ups with enhanced reporting, patient tracking

Timely follow-up imaging increased from 46% before the intervention to 55% afterward, cardiothoracic radiologists reported in JACR.

READ MORE >
lung cancer pulmonary nodule chest
Share on Twitter Share on Facebook Share on Linkedin

How one hospital bolstered incidental lung nodule follow-ups with enhanced reporting, patient tracking

Share on Twitter Share on Facebook Share on Linkedin
lung cancer pulmonary nodule chest
Timely follow-up imaging increased from 46% before the intervention to 55% afterward, cardiothoracic radiologists reported in JACR.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

TAVR for moderate aortic stenosis | BP drug recalled | Stroke prevention device fails | New Medicare cuts | CCTA-guided PCI
A new way to think about the heart health of women | GLP-1 drugs vs. metformin | Cannabis use may increase risk of CVD, stroke
New Medicare payment cuts | Telemedicine vs. in-person cardiology visits | FDA confirms Class I recall | Startup raises $160M
FDA approves transcatheter treatment for PVL | CCTA-guided PCI | Real-world RDN outcomes | J&J launches new IVL catheter
CCTA vs. IVUS for PCI guidance: Carlos Collet reviews the data | The real-world benefits of RDN | New TAVR tech falls short
TAVR Highlights: New data on treating moderate AS | CMS may expand coverage again | Is surgical backup still necessary?
GLP-1 drugs vs. metformin | BP drug recalled | The health risks of cannabis use | Energy drinks linked to heart issues
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme